IN ITALY they COULD prevent 3,000 deaths per year. Are the new super-antibiotics: reduce the mortality caused by resistant infections from 50-55% to 10-15%, a decrease of one third. Him on recent international clinical trials of phase three presented at the conference on an antibiotic resistance, organized in Genoa by the Fondazione internazionale Menarini
the news comes as the world health Organization (Who) launches an appeal. “The threat of antibiotic resistance has never been more immediate and the need for solutions more urgent,” says Tedros Adhanom Ghebreyesus , director-general of Who. “Are underway a number of initiatives to reduce the resistance, but we also need the countries and the pharmaceutical industry to step up and contribute with sustainable financing and innovative new drugs”. The fall in private investment and the lack of innovation in the development of new antibiotics are undermining efforts to fight the infections.
The bacteria that resist the antibiotics kill, in fact, each year 700,000 people in the world, with 33,000 in Europe, 10,000 in Italy. Numbers are destined to increase, but that, “by using the best and as early as the antibiotics most innovative , some already existing and others in the approval stage, there may be a decrease of a third,” explains Matteo Bassetti, president of the Italian Society for anti-infection Therapy (Sita).
The three studies have involved a thousand people with Klebsiella pneumonia and is resistant to carbapenems, and the new antibiotics tested have had positive effects. These new molecules act by inactivating the ‘poison’ produced by the bacteria to ‘kill’ the antibiotic (that is, inhibit enzymes beta). And are not the only new therapies that are available today, but, denounce experts, find it difficult to get to patients.
READ an antibiotic resistance, Italy still black jersey for infections
“Some of these have already been approved by the us Food and Drug Administration (Fda) and the European Medicines Agency (Ema), but are a barrier to use in clinical practice, for a number of reasons, including economic,” explains Marin Kollef, professor of medicine at Washington University School of Medicine. Then there is a problem of poor research. This is demonstrated by the fact that “there are only 12 in the world, the new molecules in advanced stage of clinical development in antibiotics therapy, compared with over 700 in oncology,” continues Bassetti, professor of Infectious Diseases at the University of Genoa. The paradox, he concludes, “is that the progress in surgery, trapiantologia and oncology, today allow you to save many more lives, lives that, however, we risk losing because of hospital infections from germ-resistant”.
READ the Superbugs: hospital infections driving the spread of antibiotic resistance in Europe
“The Republic will fight always in defense of the freedom of information, to its readers and to all those who have at heart the principles of democracy and civil coexistence”
Carlo Verdelli SUBSCRIBERS TO REPUBLIC © Reproduction reserved Today on Tomasi: “Now serves the peace. We will make investments, but the withdrawal we would go down” “Redesign and more controls.” The new rules for bridges and tunnels Count and the meeting with the multinational companies: “Invest in Italy, the taxes will decline,” The freedom of Sergio Referendum, Luciani: “The judges have decided in continuity with the previous cases. Makeup league did not work”
the Republic
